These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38855561)

  • 1. The connection between hypertension and diabetes and their role in heart and kidney disease development.
    Hezam AAM; Shaghdar HBM; Chen L
    J Res Med Sci; 2024; 29():22. PubMed ID: 38855561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease.
    Shen Y; Dai Y; Wang XQ; Zhang RY; Lu L; Ding FH; Shen WF
    Cardiovasc Diabetol; 2019 Nov; 18(1):160. PubMed ID: 31733658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiometabolic Risk Factors Associated With Type 2 Diabetes Mellitus: A Mechanistic Insight.
    Chakraborty S; Verma A; Garg R; Singh J; Verma H
    Clin Med Insights Endocrinol Diabetes; 2023; 16():11795514231220780. PubMed ID: 38148756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.
    Coccheri S
    Drugs; 2007; 67(7):997-1026. PubMed ID: 17488145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
    Berra C; Manfrini R; Regazzoli D; Radaelli MG; Disoteo O; Sommese C; Fiorina P; Ambrosio G; Folli F
    Pharmacol Res; 2020 Oct; 160():105052. PubMed ID: 32650058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
    Hackam DG; Khan NA; Hemmelgarn BR; Rabkin SW; Touyz RM; Campbell NR; Padwal R; Campbell TS; Lindsay MP; Hill MD; Quinn RR; Mahon JL; Herman RJ; Schiffrin EL; Ruzicka M; Larochelle P; Feldman RD; Lebel M; Poirier L; Arnold JM; Moe GW; Howlett JG; Trudeau L; Bacon SL; Petrella RJ; Milot A; Stone JA; Drouin D; Boulanger JM; Sharma M; Hamet P; Fodor G; Dresser GK; Carruthers SG; Pylypchuk G; Burgess ED; Burns KD; Vallée M; Prasad GV; Gilbert RE; Leiter LA; Jones C; Ogilvie RI; Woo V; McFarlane PA; Hegele RA; Tobe SW;
    Can J Cardiol; 2010 May; 26(5):249-58. PubMed ID: 20485689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes mellitus and hypertension: a dual threat.
    Oktay AA; Akturk HK; Jahangir E
    Curr Opin Cardiol; 2016 Jul; 31(4):402-9. PubMed ID: 27070651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
    Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.
    Khan NA; Hemmelgarn B; Herman RJ; Bell CM; Mahon JL; Leiter LA; Rabkin SW; Hill MD; Padwal R; Touyz RM; Larochelle P; Feldman RD; Schiffrin EL; Campbell NR; Moe G; Prasad R; Arnold MO; Campbell TS; Milot A; Stone JA; Jones C; Ogilvie RI; Hamet P; Fodor G; Carruthers G; Burns KD; Ruzicka M; DeChamplain J; Pylypchuk G; Petrella R; Boulanger JM; Trudeau L; Hegele RA; Woo V; McFarlane P; Vallée M; Howlett J; Bacon SL; Lindsay P; Gilbert RE; Lewanczuk RZ; Tobe S;
    Can J Cardiol; 2009 May; 25(5):287-98. PubMed ID: 19417859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.
    Serowik TC; Pantalone KM
    J Osteopath Med; 2024 Mar; 124(3):127-135. PubMed ID: 37921061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
    Khan NA; Hemmelgarn B; Herman RJ; Rabkin SW; McAlister FA; Bell CM; Touyz RM; Padwal R; Leiter LA; Mahon JL; Hill MD; Larochelle P; Feldman RD; Schiffrin EL; Campbell NR; Arnold MO; Moe G; Campbell TS; Milot A; Stone JA; Jones C; Ogilvie RI; Hamet P; Fodor G; Carruthers G; Burns KD; Ruzicka M; dechamplain J; Pylypchuk G; Petrella R; Boulanger JM; Trudeau L; Hegele RA; Woo V; McFarlane P; Vallée M; Howlett J; Katzmarzyk P; Tobe S; Lewanczuk RZ;
    Can J Cardiol; 2008 Jun; 24(6):465-75. PubMed ID: 18548143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE inhibitors. Differential use in elderly patients with hypertension.
    Israili ZH; Hall WD
    Drugs Aging; 1995 Nov; 7(5):355-71. PubMed ID: 8573991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of metabolic syndrome and chronic kidney disease.
    Scurt FG; Ganz MJ; Herzog C; Bose K; Mertens PR; Chatzikyrkou C
    Obes Rev; 2024 Jan; 25(1):e13649. PubMed ID: 37783465
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.